Remember, if the 3 compassionate use cases from last Q made it to this Q, the company charges them $25K for boosters (twice a year) and potentially another $100K for repeat manufacturing if they have tumor but not enough vaccine doses. If they did that and maybe got a few more new patients signed up they could almost double the miniscule revenue on 3 patients.